Praxbind® (idarucizumab) licensed in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

  1. Idarucizumab is the first specific reversal agent for a NOAC to receive European licence1
  2. Idarucizumab immediately reverses the anticoagulant effect of dabigatran2-4

Bracknell, United Kingdom - 26th November 2015 – The European Commission has licensed Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.1 Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be granted a licence in the European Union.1

Continue Reading

Award Success for new CLOT Secretary

New CLOT secretary Jodie Williams was part of the AF and Stroke Prevention  team that won an Innovation award for 2015. Congratulations from all at CLOT

 

 

Save The Date CLOT Conference 2016

Following another successful conference CLOT are always looking to the future. The date for the conference in 2016 will be Friday 14/10/16 more details to follow.

AEGEAN trial results: Does patient education actually matter?

An educational programme to encourage adherence to the new anticoagulant apixaban (Eliquis, Bristol Myers-Squibb), in the first 6 months of treatment in AF patients made no difference to compliance rates in the Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) study

Education included a patient information booklet explaining AF and anticoagulant treatment for stroke prevention, reminder tools (key ring, mobile phone alerts), and access to a virtual clinic with staff from existing anticoagulation clinics. Adherence was measured using an electronic device that holds a blister pack of medication and records each time the pack is removed. At 24 weeks, the adherence rate was 88.5% in the control group and 88.3% in the education group (P=0.89), and persistence rates were 90.5% and 91.1% respectively (P=0.76).

Whether these figures persist longer than 24 weeks remains to be seen. Long term adherence to a medication regimen may be more difficult to achieve without professional support.